Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance

Blood (2024) 144 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2024-200798

Published: 2024

Journal Articles

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Blood (2022) 140 (Supplement 1): 1773–1774.

https://doi.org/10.1182/blood-2022-162157

Published: 2022

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Blood (2019) 134 (Supplement_1): 4073.

https://doi.org/10.1182/blood-2019-122948

Published: 2019

Journal Articles

Mutation Profile of PPM1D and TP53 in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

Blood (2019) 134 (Supplement_1): 2994.

https://doi.org/10.1182/blood-2019-126778

Published: 2019

Journal Articles

TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Blood (2019) 134 (Supplement_1): 3007.

https://doi.org/10.1182/blood-2019-126671

Published: 2019

Journal Articles

Molecular Profile and Cytomorphological Manifestation of Isolated Y Loss in Myelodysplastic Syndromes

Blood (2018) 132 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2018-99-114216

Published: 2018

Journal Articles

Acquisition Patterns and Interaction of Molecular, Obvious and Cryptic Cytogenetic Abnormalities in Myelodysplastic Syndromes

Christina Ganster, Katayoon Shirneshan, Sascha Dierks, Roman Martin, Bertram Glass, Haifa Kathrin Al-Ali, Michael Metz, Ulrich Germing, MD, Uwe Platzbecker, MD, Nicolaus Kroeger, Friederike Braulke, Julie Schanz, Lorenz Truemper, Detlef Haase

Blood (2017) 130 (Supplement 1): 4260.

https://doi.org/10.1182/blood.V130.Suppl_1.4260.4260

Published: 2017

Journal Articles

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Julie Schanz, MD PhD, Friederike Braulke, MD, Ghulam J. Mufti, MD PhD, Elena Crisà, Austin Kulasekararaj, Kathrin Nachtkamp, MD, Ulrich Germing, Stefan Schmitz, MD PhD, Peter Haas, MD, Michael Lübbert, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, Florian Nolte, Wolf-Karsten Hofmann, MD PhD, Detlef Haase

Blood (2014) 124 (21): 4656.

https://doi.org/10.1182/blood.V124.21.4656.4656

Published: 2014

Journal Articles

Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide Monotherapy Reveals 82% Cytogenetic Responders With Different Response – , Evolutionary -, and Remission Patterns and No Increased Karyotype Evolution (KE)

Katayoon Shirneshan, PhD, Uwe Platzbecker, MD, PhD, Florian Nolte, MD, Aristoteles Giagounidis, MD, Katharina Götze, M.D., Richard F. Schlenk, MD, Michael Lübbert, MD, Gesine Bug, MD, PhD, Friederike Braulke, Julie Schanz, MD, Ulrich Germing, MD, Detlef Haase, MD

Blood (2013) 122 (21): 2783.

https://doi.org/10.1182/blood.V122.21.2783.2783

Published: 2013

Journal Articles

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Julie Schanz, MD, Friederike Braulke, Katayoon Shirneshan, PhD, Kathrin Nachtkamp, MD, Ulrich Germing, MD, Stephan Schmitz, MD, Peter Haas, MD, Michael Lübbert, MD, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, PhD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD, Detlef Haase, MD

Blood (2013) 122 (21): 2784.

https://doi.org/10.1182/blood.V122.21.2784.2784

Published: 2013

Journal Articles

A Comprehensive Genetic Analysis of MDS Patients From Peripheral Blood Combining FISH- and SNP-Array-Analysis

Christina Ganster, Katayoon Shirneshan, Gabriela Salinas-Riester, Friederike Braulke, Julie Schanz, Katharina S. Götze, Gesine Bug, Peter Majunke, Aristoteles Giagounidis, Catharina Müller-Thomas, Andrea Kündgen, Ulrich Germing, Lorenz Trümper, Uwe Platzbecker, MD, Detlef Haase

Blood (2012) 120 (21): 4926.

https://doi.org/10.1182/blood.V120.21.4926.4926

Published: 2012

Journal Articles

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

Blood (2012) 120 (21): 3816.

https://doi.org/10.1182/blood.V120.21.3816.3816

Published: 2012

Journal Articles

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

Uwe Platzbecker, MD, Friederike Braulke, Andrea Kuendgen, Katharina S. Götze, Gesine Bug, Katayoon Shirneshan, Christoph Röllig, Martin Bornhäuser, MD, Ralph Naumann, MD, Jürgen Neesen, Aristoteles Giagounidis, MD, Wolf-Karsten Hofmann, Gerhard Ehninger, Prof., Ulrich Germing, MD, Detlef Haase, Martin Wermke, MD

Blood (2012) 120 (21): 921.

https://doi.org/10.1182/blood.V120.21.921.921

Published: 2012

Journal Articles

Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial,

Uwe Platzbecker, MD, Christina Ganster, Jürgen Neesen, Andrea Kuendgen, MD, Katharina Götze, Gesine Bug, Katayoon Shirneshan, Friederike Braulke, Christoph Röllig, MD, Ralph Naumann, MD, Eckhard Büssemaker, Aristoteles Giagounidis, MD, Wolf-Karsten Hofmann, MD, Ulrich Germing, MD, Detlef Haase, Gerhard Ehninger, MD

Blood (2011) 118 (21): 3799.

https://doi.org/10.1182/blood.V118.21.3799.3799

Published: 2011

Journal Articles

Proof of Y-Loss As Clonal Abnormality in MDS by Comparative Analysis of CD34+ and CD3+ Peripheral Blood Cells,

Christina Ganster, Friederike Braulke, Katayoon Shirneshan, Dietrich Kämpfe, Uwe Platzbecker, MD, Ulrike Söling, Carsten P Bramlage, Tobias J Legler, Detlef Haase, Julie Schanz

Blood (2011) 118 (21): 3800.

https://doi.org/10.1182/blood.V118.21.3800.3800

Published: 2011

Journal Articles

Genetic Response to Lenalidomide in the Circulating Progenitor Cell Compartment of MDS Cohort. Preliminary Results of the Multicenter German LE-MON-5 Study

Katayoon Shirneshan, Ulrich Germing, Friederike Braulke, Julie Schanz, Uwe Platzbecker, MD, Aristoteles Giagounidis, Florian Nolte, Katharina Götze, Detlef Haase

Blood (2011) 118 (21): 1721.

https://doi.org/10.1182/blood.V118.21.1721.1721

Published: 2011

Journal Articles

Chromosomal Aberrations Identified in CD34+ Peripheral Blood Cells of MDS Patients by FISH- and SNP Array Analysis

Christina Ganster, Katayoon Shirneshan, Gabriela Salinas-Riester, Friederike Braulke, Katharina Götze, Uwe Platzbecker, MD, Detlef Haase

Blood (2011) 118 (21): 4872.

https://doi.org/10.1182/blood.V118.21.4872.4872

Published: 2011

Journal Articles

Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study

Friederike Braulke, MD, Julie Schanz, MD, Michael Metz, MD, Sven Detken, MD, Joerg Seraphin, MD, Katharina Götze, MD, Catharina Mueller-Thomas, MD, Uwe Platzbecker, MD, Tim Henrik Brümmendorf, MD, Aristoteles A.N. Giagounidis, MD, Ulrich Germing, MD, Kathleen Jentsch-Ullrich, MD, Angelika Boehme, MD, Gesine Bug, MD, Oliver G. Ottmann, Prof, Dr., med., Philippe Schafhausen, MD, Lorenz Trümper, MD, Detlef Haase, MD

Blood (2010) 116 (21): 2937.

https://doi.org/10.1182/blood.V116.21.2937.2937

Published: 2010

Journal Articles

A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial

Uwe Platzbecker, Detlef Haase, Friederike Braulke, Gesine Bug, Katharina Götze, Andrea Kuendgen, Christoph Röllig, Martin Wermke, Ralph Naumann, Martin Bornhäuser, Aristoteles Giagounidis, Ulrich Germing, Wolf-Karsten Hofmann, Gerhard Ehninger

Blood (2010) 116 (21): 4000.

https://doi.org/10.1182/blood.V116.21.4000.4000

Published: 2010

NARROW

Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Mutation Profile of PPM1D and TP53 in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Molecular Profile and Cytomorphological Manifestation of Isolated Y Loss in Myelodysplastic Syndromes

Acquisition Patterns and Interaction of Molecular, Obvious and Cryptic Cytogenetic Abnormalities in Myelodysplastic Syndromes

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

A Comprehensive Genetic Analysis of MDS Patients From Peripheral Blood Combining FISH- and SNP-Array-Analysis

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial,

Proof of Y-Loss As Clonal Abnormality in MDS by Comparative Analysis of CD34+ and CD3+ Peripheral Blood Cells,

Genetic Response to Lenalidomide in the Circulating Progenitor Cell Compartment of MDS Cohort. Preliminary Results of the Multicenter German LE-MON-5 Study

Chromosomal Aberrations Identified in CD34+ Peripheral Blood Cells of MDS Patients by FISH- and SNP Array Analysis

Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study

A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only